Compare MLKN & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | SGP |
|---|---|---|
| Founded | 1905 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 932.9M |
| IPO Year | 1994 | N/A |
| Metric | MLKN | SGP |
|---|---|---|
| Price | $15.50 | $21.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 625.8K | 51.9K |
| Earning Date | 03-25-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $20.15 |
| 52 Week High | $23.18 | $30.56 |
| Indicator | MLKN | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 36.44 |
| Support Level | $15.36 | N/A |
| Resistance Level | $16.34 | $26.29 |
| Average True Range (ATR) | 0.57 | 1.54 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 57.63 | 2.59 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.